132 stories
Semaglutide is the active ingredient in Ozempic and Wegovy. Novo Nordisk holds the patent in most markets through 2031, but the Indian patent expired in March 2026 and a wave of generics from Biocon, Dr. Reddy's, and others followed within weeks.
The cardiovascular and renal evidence has expanded fastest. SELECT showed a 20% reduction in MACE for non-diabetic adults with obesity. The REMODEL trial (presented at the World Congress of Nephrology 2026) showed direct kidney protection independent of weight loss. Cell Metabolism work from Sinai Health pinned MASH reversal to liver sinusoidal endothelial cells, not weight loss or appetite. JAMA published a 90,000-patient HFpEF analysis showing a 42% reduction in heart-failure hospitalization or all-cause mortality.
The compounding story keeps moving in parallel. The FDA proposed excluding semaglutide from the 503B bulks list on April 30, 2026, with public comment open through June 29. Tirzepatide and liraglutide were folded into the same proposal.
On September 7, 2026, Novo reported first Phase 3 results in children under 12: the STEP Young trial in 165 children aged 6 to under 12 years with obesity showed 40.4% below the obesity threshold at week 68 on semaglutide (max 1.7 mg or 2.4 mg by baseline weight) plus lifestyle modification, versus 0% on placebo; safety matched adult and adolescent experience, with no signal for growth or pubertal development. Detailed results are due at ObesityWeek 2026 in Washington DC (November 14-17). A supplemental filing to extend the U.S. Wegovy label below the current 12-and-older indication has not been announced.
Comprehensive review examining GLP-1 receptor agonists for neurological conditions. A recent NEJM trial showed GLP-1 treatment resulted in less motor disability progression at 12 months.
Amazon Pharmacy expanded access to the new oral Wegovy pill with both insurance and cash-pay options, signaling a broader retail push to capitalize on surging oral GLP-1 demand.
Injectable semaglutide and tirzepatide will drop to ~$350/month initially and $245/month within two years, down from current list prices of $1,000–$1,350/month.
The ACHIEVE-3 trial in The Lancet showed Eli Lilly's Foundayo (orforglipron) superior on HbA1c, while Novo Nordisk's oral Wegovy may have an edge in weight-loss efficacy.
Phase IIIb results show investigational 7.2 mg semaglutide dose produced 21% mean weight loss in adults with obesity without diabetes, with a tolerable safety profile.
Industry analysis highlights CagriSema (cagrilintide + semaglutide) Phase 3 data showing 14.2% weight loss in type 2 diabetes adults, positioning it as a major Novo Nordisk pipeline asset.
Psychiatric Times provides educational review of the incretin system covering the shift toward oral nonpeptide small-molecule GLP-1 RAs and triple agonists expected within 1-2 years.
Analysis covers Novo's competitive positioning including ORION study results comparing oral semaglutide against orforglipron, plus up to 48% price cuts in India.
WeightWatchers began offering oral Wegovy with promotional pricing. Clinical trials showed 13.6% body weight loss with oral formulation versus 14.9% injectable.
GoodRx announced oral semaglutide availability via its telemedicine platform at $149 for lower doses, matching Novo Nordisk pricing and intensifying the GLP-1 price war.
India's drug regulators are intensifying GLP-1 oversight ahead of semaglutide's patent expiry. The Drug Controller General audited 49 entities and issued notices to violators.
The FLOW trial showed semaglutide reduced major kidney disease events by ~24%, while the SELECT trial found a 20% reduction in major adverse cardiovascular events among 17,600+ adults.
The 25-mg oral semaglutide formulation broadens GLP-1 access for chronic weight management, with pharmacists playing a key role in patient counseling and adherence support.
Published the day after Foundayo's FDA approval, a new indirect comparison found oral semaglutide may produce greater weight loss than orforglipron with fewer GI discontinuations.
Analysis of the FAERS database (2012–2025) examining exenatide, liraglutide, dulaglutide, semaglutide, and tirzepatide reveals distinct risk profiles, suggesting not all GLP-1 agents carry the same safety concerns.
Managed Healthcare Executive compares Foundayo (orforglipron) vs oral Wegovy (semaglutide). ACHIEVE-3 trial data showed Foundayo superior on HbA1c, but oral Wegovy may edge ahead on weight loss.
A new study identified a potential link between semaglutide use and a rare dermatological pain syndrome. Researchers also referenced Phase 2 retatrutide data as part of broader incretin safety analysis.
India's Central Drugs Standard Control Organization issued advisories against unsupervised use of semaglutide and tirzepatide for weight loss, cracking down on misleading social media promotions and unapproved compounded versions.